NCT06698198

Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine Candidate in Healthy Adults (19-49 Years)

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 175 (actual)
• Sponsor: Sanofi Pasteur, a Sanofi Company · Industry
• Sex: All
• Age: 19 Years – 49 Years
• Healthy volunteers: Accepted

Summary

This was a Phase I, randomized, active-controlled, observer-blinded, multi-center study to assess the safety and the immunogenicity of 4 Pneumococcal Conjugate Vaccines (PCV) candidates in parallel with Prevnar 13, in Healthy Adults (19-49 years) in the United States.

Conditions

• Pneumococcal Immunization

Interventions

Type	Name	Description
BIOLOGICAL	Pneumococcal Conjugate Vaccine	Suspension for Intramuscular injection
BIOLOGICAL	Prevnar 13®	Suspension for Intramuscular injection

Timeline

• Start date: 2018-12-03
• Primary completion: 2019-09-30
• Completion: 2019-09-30
• First posted: 2024-11-20
• Last updated: 2024-11-20

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study